FDA Approves Bayer’s Nuqeba for Metastatic Castration-Sensitive Prostate Cancer
June 4th 2025Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of radiographic progression or death when combined with androgen deprivation therapy, in patients with metastatic castration-sensitive prostate cancer.
Teva Unveils Positive Data for Uzedy, TEV-'749 in Schizophrenia
June 3rd 2025New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong efficacy with no post-injection delirium/sedation syndrome to date—advancing long-acting treatment options for schizophrenia.
Bristol Myers Squibb, BioNTech Partner to Develop Next-Gen Bispecific Antibody for Solid Tumors
June 2nd 2025Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the option to pursue additional indications and combination therapies independently.
Guiding Pharma Through Geopolitical Uncertainty: Q&A with the Federated Healthcare Advisory Panel
May 27th 2025In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Amgen Aims to Cut US Cardiovascular Events by 50% by 2030
May 20th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk through free LDL-C testing, public-private partnerships, and implementation science initiatives—all aimed at cutting CV events in half by 2030.
Improving Care Transitions for Cardiovascular Patients: Key Insights for Doctors
May 19th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across primary care, cardiology, and rehabilitation are critical to improving outcomes and preventing care gaps for cardiovascular patients.